Sugi Predict

Sugi Predict / Compounds / SCHEMBL18007604

SCHEMBL18007604

SCHEMBL18007604

CCOC(=O)c1cc(S(N)(=O)=O)nn1C

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.46
▸ RAB9A P51151 4/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ MAPT P10636 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CA9 Q16790 4/20 0.40
▸ CA1 P00915 4/20 0.40
▸ CA2 P00918 4/20 0.40
▸ CA12 O43570 2/20 0.40
▸ FAAH O00519 1/20 0.39
▸ STS P08842 1/20 0.39
▸ CHRNA7 P36544 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18007685 0.85 LMNA (0.49) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL19508023 0.83 ALDH1A1 (0.40) NPC1SMN1; SMN2KDM4ECA9CA1
SCHEMBL22680981 0.83 RAB9A (0.50) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL25033912 0.82 CA9 (0.40) LMNASMN1; SMN2CA9CA1CA2
SCHEMBL20743212 0.82 SMN1; SMN2 (0.41) SMN1; SMN2MAPTCA9CA1CA2
SCHEMBL19507069 0.79 CA9 (0.56) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL19507068 0.79 CA9 (0.54) LMNARAB9ANPC1SMN1; SMN2KDM4E
SCHEMBL8072052 0.78 LMNA (0.56) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL286585 0.78 LMNA (0.50) LMNARAB9ANPC1SMN1; SMN2MAPT
SCHEMBL20760989 0.78 CA12 (0.32) MAPTMEN1KMT2ACA9CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12221434-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2025-02-11 — — US disclosed
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME UNIV QUEENSLAND (AU) 2024-12-05 — — US disclosed
CN-113582889-B Sulfonylureas and related compounds and uses thereof 昆士兰大学 2024-09-20 — — CN disclosed
US-12012392-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2024-06-18 — — US disclosed
US-11905252-B2 Compounds INFLAZOME LIMITED (IE) 2024-02-20 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
US-11845715-B2 — — 2023-12-19 — — US disclosed
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 — — CN disclosed
US-11613542-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors INFLAZOME LIMITED (IE) 2023-03-28 — — US disclosed
WO-2019034688-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034690-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034692-A1 SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
WO-2019034686-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2019-02-21 — — WO disclosed
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME INFLAZOME LIMITED (IE) 2018-02-15 — — US disclosed
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME INFLAZOME LIMITED (IE) 2018-02-15 — — US disclosed
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME INFLAZOME LIMITED (IE) 2018-02-15 — — US disclosed
EP-3259253-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME The University of Queensland (AU) 2017-12-27 — — EP disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 — — WO disclosed
WO-2016131098-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME THE UNIVERSITY OF QUEENSLAND (AU) 2016-08-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11905252-B2 Compounds NLRP3, NOD1, PYCARD LMNA 809/4885RAB9A 3000/4885NPC1 124/4885
US-11845715-B2 — NLRP3, PYCARD, NOD1 LMNA 2579/4885RAB9A 3413/4885NPC1 255/4885
US-20240400502-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP LMNA 2731/4885RAB9A 3614/4885NPC1 799/4885
US-12221434-B2 Sulfonamide carboxamide compounds NLRP3, PYCARD, NOD1 LMNA 2242/4885RAB9A 3799/4885NPC1 400/4885
US-20180044287-A1 SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME NLRP3, PYCARD, IAPP LMNA 2731/4885RAB9A 3614/4885NPC1 799/4885
US-12012392-B2 Sulfonamide carboxamide compounds NLRP3, PYCARD, NOD1 LMNA 1939/4885RAB9A 4158/4885NPC1 381/4885
US-11613542-B2 Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors NLRP3, NOD1, NLRP1 LMNA 1441/4885RAB9A 2868/4885NPC1 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.